Richard G. Harris, MD, led a panel discussion on “Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19” for the Grand Rounds in Urology audience in June, 2020.
How to cite: Harris, Richard G. Langford, Timothy D. Saltzstein, Daniel R. Crawford, E. David. “Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19” June, 2020. Accessed Apr 2024. https://dev.grandroundsinurology.com/managing-prostate-cancer-patients-and-lhrh-injection-times-during-covid-19/
Managing Prostate Cancer Patients and LHRH Injection Times During COVID-19 – Summary:
Richard Harris, MD, President of LUGPA and CEO of UroPartners, moderates a discussion between Daniel R. Saltzstein, MD, from Urology San Antonio, and Timothy D. Langford, MD, from Arkansas Urology. They discuss the challenges of managing prostate cancer patients during COVID-19, including the ways the pandemic has changed the manner and frequency of how they bring in patients in for treatment, particularly for therapies like androgen deprivation. Both Dr. Saltzstein and Dr. Langford emphasize the precautions they are taking at their practices to address the risks of COVID-19, and acknowledge how challenging this patient population can be given their need for frequent visits. They highlight the limitations of telehealth, as well as the risks of not bringing patients in often enough to receive the therapies that they need, even though lengthening the time between visits has been the answer a lot of doctors have found to reduce the risk of COVID-19 exposure.
To expand your knowledge of androgen deprivation therapy, visit our ADT Next Generation Learning Center.
